NEUROGENE
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.
NEUROGENE
Industry:
Biotechnology
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.neurogene.com
Total Employee:
11+
Status:
Active
Total Funding:
68.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Board_member
2019-02-01
Current Employees Featured
Rachel McMinn President & CEO @ Neurogene
President & CEO
2018-01-01
Steve Pincus Executive Director Analytical Development @ Neurogene
Executive Director Analytical Development
2021-02-01
Founder
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series A - Neurogene
Samsara BioCapital
Samsara BioCapital investment in Series A - Neurogene
Redmile Group
Redmile Group investment in Series A - Neurogene
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Neurogene
Official Site Inspections
http://www.neurogene.com Semrush global rank: 3.58 M Semrush visits lastest month: 4.02 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neurogene"
Neurogene – Global Initiative in Neuropsychiatric Ethics
NeuroGenE is the Global Initiative in Neuropsychiatric Ethics based at the University of Oxford. We conduct global multidisciplinary research and capacity-building on the ethics of diagnosis, …See details»
About – Neurogene
NeuroGenE is a global research and capacity-building initiative exploring the multi-layered ethical challenges around psychiatry and neurodevelopmental diagnosis, prevention and intervention.See details»
Neurogene | Developing life-changing Genetic Medicines
Neurogene is focused on developing life-changing genetic medicines for patients & families affected by rare, devastating neurological diseases.See details»
Research – Neurogene
The NeuroGenE research programme examines the ethical challenges to the scientific research, and clinical and public policy application, of psychiatric genetics and genomics research with …See details»
Neurogene | About Us & the Future of Genetics in Medicine
Nov 13, 2018 · At Neurogene, our focus is to develop life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. Push the boundaries of …See details»
Neurogene | Our focus on Breakthroughs in Genetic …
Neurogene is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. To accomplish this, we collaborate with many researchers, the patient …See details»
Neurogene - The Org
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to …See details»
Neurogene Inc. | Neurogene Reports Positive Interim Efficacy Data …
Nov 11, 2024 · Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will …See details»
Ilina Singh's lab | University of Oxford (OX) - ResearchGate
NeuroGenE is the Global Initiative in Neuropsychiatric GenEthics based at the University of Oxford. We conduct global multidisciplinary research, training, and capacity-building on the …See details»
Neurogene - Crunchbase Company Profile & Funding
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders. View contacts for Neurogene to access new leads and connect with …See details»
People – Neurogene
As core researchers of NeuroGenE, the Oxford team is comprised of interdisciplinary academics with particular research expertise in global mental health; neuroethics; disability rights and mental health advocacy; and …See details»
Neurogene Inc. | Investor Relations
Nov 18, 2024 · The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing …See details»
Neurogene Inc. | Neurogene Provides Update on NGN-401 Gene …
Nov 18, 2024 · NEW YORK --(BUSINESS WIRE)--Nov. 18, 2024-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients …See details»
Rachel McMinn - CEO at Neurogene - The Org
Dr. McMinn founded Neurogene in January 2018 with the mission of providing genetic medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their …See details»
Neurogene's CEO and Executive Team - Team members and org …
Neurogene's CEO and Executive Team includes Ricardo Jimenez and 7 others.See details»
Who Funds Us – Neurogene
NeuroGenE receives core funding from the Stanley Centre for Psychiatric Research at the Broad Institute of Harvard and MIT. To date, we have received further support from the Wellcome …See details»
Additional Resources - Neurogene
Global Genes is an organization that helps to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for …See details»
Neurogene Releases Update on NGN-401 Clinical Trial High Dose
Nov 18, 2024 · You can read more details in Neurogene’s release in the link below. The key information that Neurogene shared is that one patient, the child who was the third to receive …See details»
Funders & Partners – Neurogene
We rely on our funders and partners to ensure we achieve our main goal of establishing a world-class model for sustainable and integrated research, capacity-building, and training initiatives …See details»
Trofinetide benefits the ability to communicate in Rett syndrome: a ...
Nov 18, 2024 · AK Percy is coeditor of Translational Science of Rare Diseases, received research funding from the National Institutes of Health, and is a consultant for Acadia Pharmaceuticals …See details»